GLP-1 receptor agonists — the peptide drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — were developed to treat type 2 diabetes and were later approved separately for chronic weight management in adults meeting specified criteria.^[1] Within roughly two years of the weight-management approvals reaching critical cultural mass, the conversation began to expand well beyond endocrinology clinics. Retired professional athletes disclosed use, sometimes for weight and sometimes for obstructive sleep apnea.^[2] Broadcast commentators folded the drugs into routine cultural shorthand. And anti-doping bodies placed the class on the WADA Monitoring Program in advance of a possible classification decision.^[3]

Why sport is having this conversation now

For most of the modern anti-doping era, weight-loss medications have not been a live issue in elite sport. The drugs available were either ineffective, poorly tolerated, or associated with adverse events severe enough to keep them out of general use. GLP-1 receptor agonists changed the picture by combining meaningful, sustained weight reduction in the approved indications with a tolerability profile — dominated by gastrointestinal effects during dose escalation — that most patients can navigate. That combination is what has made the class a cultural phenomenon; it is also what has made it a topic that governance bodies now have to consider.

The regulatory frame

GLP-1 agonists in their approved brand-drug form are FDA-approved prescription medications, prescribed and dispensed through the standard pharmacy system, not research peptides sold with 'not for human consumption' labeling.^[1] Tirzepatide additionally acts on the GIP receptor — a distinguishing pharmacological feature relative to the pure GLP-1 agonists. Compounded versions sit in a separate regulatory category that the FDA has been actively narrowing since the 2025 resolutions of the semaglutide and tirzepatide shortages, with warnings issued to more than fifty compounders over the course of that year.^[4]

For an athlete or coach trying to make sense of the coverage, that regulatory divide is doing important work. An athlete prescribed Wegovy for a documented medical indication is inside one regulatory system; an athlete sourcing 'research use only' semaglutide from an online seller is inside a different one, with different implications for testing, labeling, and dose accuracy.

The anti-doping question

As of the current WADA cycle, GLP-1 receptor agonists appear on the WADA Monitoring Program rather than on the Prohibited List.^[3] Placement on the Monitoring Program is not a ban and does not by itself trigger sanctions. It is a data-collection posture: WADA and its accredited laboratories look for the class in samples to build a picture of prevalence in competition and out of competition, and to inform any subsequent classification decision. The public reasoning for monitoring the GLP-1 class has centered on the meaningful body-composition changes the drugs produce in their approved indications and the incomplete understanding of what long-term use might mean for healthy, trained athletes.

What the athletic-performance evidence does — and does not — establish

The randomized clinical evidence on GLP-1 agonists is anchored in the diabetes and obesity indications for which the drugs were developed. Large trials document weight reduction; the outcomes trial for semaglutide in a defined obese adult population with cardiovascular disease established a reduction in major adverse cardiovascular events.^[5] A meaningful fraction of the weight lost during GLP-1 treatment is lean mass, a finding that complicates any naive 'this will help performance' reading.^[1]

There is no adequately powered clinical program characterizing the performance effects of these drugs in healthy, trained athletes. The absence is not evidence of harm; it is an absence, which is exactly why WADA's monitoring posture is a monitoring posture rather than a classification one.

The disclosures shaping the coverage

The current cycle of coverage has been driven in part by high-profile disclosures. Shaquille O'Neal has spoken publicly about using Zepbound for obstructive sleep apnea, an FDA-approved indication for tirzepatide, in the context of a paid Eli Lilly campaign.^[2] Serena Williams disclosed use for postpartum weight in the context of a paid partnership with a telehealth company through which she received the prescription. Each disclosure operates inside its own commercial relationship structure, and each has been reported alongside those relationships.

What the pivotal trials measured in patients

The GLP-1 weight-management programs did not only track scale weight. In the STEP 1 trial of semaglutide, participants receiving active drug reported improvements over placebo on the SF-36 physical-functioning score and the IWQOL-Lite-CT — validated patient-reported outcome instruments used widely in the obesity-medicine literature to capture how weight affects daily physical activity and quality of life.^[6] The SURMOUNT-1 program for tirzepatide reported directionally similar patient-reported outcome findings on comparable instruments.^[7] These are prospectively defined measurements collected inside randomized trials, not anecdotes — and they are the layer of the evidence base most directly relevant to how patients in the approved indications describe feeling on the drugs.

The frame that keeps holding

Two facts should stay foregrounded when reading coverage in this space. First: brand-drug GLP-1 receptor agonists are FDA-approved prescription medications; research-channel versions are not. Second: the class is currently on WADA's Monitoring Program, which means it is not banned but is being watched. Coverage that collapses either of those distinctions is producing more heat than light.